Connect Biopharma Presents Abstract About Results From Rademikibart Global Phase 2b Trial In Patients With Moderate-to-severe Asthma At ATS 2024 international Conference
Portfolio Pulse from Benzinga Newsdesk
Connect Biopharma presented positive results from its Phase 2b trial of Rademikibart for moderate-to-severe asthma at the ATS 2024 conference. The treatment showed significant improvements in lung function and asthma control, sustained through Week 24. An End of Phase 2 meeting with the FDA is scheduled for Q2 2024.
May 22, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Connect Biopharma's Rademikibart demonstrated significant improvements in lung function and asthma control in a Phase 2b trial, with results presented at ATS 2024. An FDA meeting is scheduled for Q2 2024.
The positive trial results and upcoming FDA meeting are likely to boost investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100